liquiritigenin has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, D; Du, J; Du, P; Gao, H; Liang, F; Yin, L; Yue, J; Zhang, H; Zhang, N; Zhao, B | 1 |
| Emons, G; Girgert, R; Gründker, C; Hinsche, O | 1 |
2 other study(ies) available for liquiritigenin and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Liquiritigenin decreases tumorigenesis by inhibiting DNMT activity and increasing BRCA1 transcriptional activity in triple-negative breast cancer.
Topics: Apoptosis; BRCA1 Protein; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Flavanones; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Promoter Regions, Genetic; Transcription, Genetic; Triple Negative Breast Neoplasms | 2021 |
Estrogen receptor β selective agonists reduce invasiveness of triple-negative breast cancer cells.
Topics: Cell Movement; Cell Proliferation; Coculture Techniques; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Flavanones; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Neoplasm Invasiveness; Oxazoles; Receptors, CXCR4; Triple Negative Breast Neoplasms | 2015 |